Follow today's market news in real time: CAC 40 prices, corporate announcements, financial releases and market information. This page automatically aggregates the latest briefs and press releases to give you the most up-to-date view of the moves driving the session.
ASM International has experienced a 4.76% decrease midday this Thursday, January 8, 2026, bringing its price down to 600.40 euros from 630.40 euros the previous…
BNP Paribas is up 2.31% at 81.54 euros this Thursday midday after UBS's spectacular upgrade from neutral to buy, with a revised price target from 77.40 to 103 e…
Pernod Ricard's share price has increased by 2.31% to EUR 73.64 at midday this Thursday, January 8, after hitting its technical support level at EUR 71.98. With…
STMicroelectronics shares have fallen by 1.32% to 24.37 euros this Thursday, January 8th at midday, following an 8.6% increase over the past seven days. This co…
Schneider Electric drops by 1.98% to 239.60 euros at midday on January 8, despite Bernstein's target increase to 285 euros published the previous day. This move…
Rémy Cointreau's stock has risen by 6.56% at midday on January 8, reaching 39.66 euros, in a technical rebound following a 14.97% correction over three months. …
French cloud service provider OVHcloud reported revenue of 275.3 million euros for the first quarter of its 2026 fiscal year on Wednesday, reflecting an organic…
The French group specializing in contract catering and services released its first-quarter results for the 2026 fiscal year on Wednesday. Sodexo reported consol…
Societe Generale's stock rises 1.1% to 69.88 euros at midday on January 8, 2026, approaching its resistance level at 70.32 euros. This increase is supported by …
Saint-Gobain's stock falls sharply following a downgrade by UBS, reflecting a challenging outlook in the US and a slow recovery in Europe.
Renault's stock price has fallen by 3.26% this Thursday, January 8, trading at 33.55 euros, down from 34.68 euros at the previous day's close. The trading volum…
The French biopharmaceutical group AB Science announced on the evening of January 7 a fourth consecutive clinical response observed with the combination of AB89…
DISCLAIMER: This information is not contractual in nature and carries no guarantee of accuracy. It should not be considered investment advice. Ideal-investisseur.fr cannot be held liable for any damages or losses arising from the use of this information.
